Literature DB >> 21878982

Targeting cancer metabolism: a therapeutic window opens.

Matthew G Vander Heiden1.   

Abstract

Genetic events in cancer activate signalling pathways that alter cell metabolism. Clinical evidence has linked cell metabolism with cancer outcomes. Together, these observations have raised interest in targeting metabolic enzymes for cancer therapy, but they have also raised concerns that these therapies would have unacceptable effects on normal cells. However, some of the first cancer therapies that were developed target the specific metabolic needs of cancer cells and remain effective agents in the clinic today. Research into how changes in cell metabolism promote tumour growth has accelerated in recent years. This has refocused efforts to target metabolic dependencies of cancer cells as a selective anticancer strategy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21878982     DOI: 10.1038/nrd3504

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  166 in total

1.  A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth.

Authors:  Sébastien Bonnet; Stephen L Archer; Joan Allalunis-Turner; Alois Haromy; Christian Beaulieu; Richard Thompson; Christopher T Lee; Gary D Lopaschuk; Lakshmi Puttagunta; Sandra Bonnet; Gwyneth Harry; Kyoko Hashimoto; Christopher J Porter; Miguel A Andrade; Bernard Thebaud; Evangelos D Michelakis
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

2.  Resolving the distinct stages in erythroid differentiation based on dynamic changes in membrane protein expression during erythropoiesis.

Authors:  Ke Chen; Jing Liu; Susanne Heck; Joel A Chasis; Xiuli An; Narla Mohandas
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-28       Impact factor: 11.205

Review 3.  Cancer chemotherapy--the first twenty-five years.

Authors:  R B Scott
Journal:  Br Med J       Date:  1970-10-31

4.  Evidence for an alternative glycolytic pathway in rapidly proliferating cells.

Authors:  Matthew G Vander Heiden; Jason W Locasale; Kenneth D Swanson; Hadar Sharfi; Greg J Heffron; Daniel Amador-Noguez; Heather R Christofk; Gerhard Wagner; Joshua D Rabinowitz; John M Asara; Lewis C Cantley
Journal:  Science       Date:  2010-09-17       Impact factor: 47.728

5.  ATP citrate lyase inhibition can suppress tumor cell growth.

Authors:  Georgia Hatzivassiliou; Fangping Zhao; Daniel E Bauer; Charalambos Andreadis; Anthony N Shaw; Dashyant Dhanak; Sunil R Hingorani; David A Tuveson; Craig B Thompson
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

6.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

7.  Isotype-specific inhibitors of the glycolytic key regulator pyruvate kinase subtype M2 moderately decelerate tumor cell proliferation.

Authors:  Gilles A Spoden; Sybille Mazurek; Dieter Morandell; Nicole Bacher; Michael J Ausserlechner; Pidder Jansen-Dürr; Erich Eigenbrodt; Werner Zwerschke
Journal:  Int J Cancer       Date:  2008-07-15       Impact factor: 7.396

8.  Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.

Authors:  Mary Ann Weiser; Maria E Cabanillas; Marina Konopleva; Deborah A Thomas; Sherry A Pierce; Carmen P Escalante; Hagop M Kantarjian; Susan M O'Brien
Journal:  Cancer       Date:  2004-03-15       Impact factor: 6.860

9.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

Authors:  Wei Xu; Hui Yang; Ying Liu; Ying Yang; Ping Wang; Se-Hee Kim; Shinsuke Ito; Chen Yang; Pu Wang; Meng-Tao Xiao; Li-xia Liu; Wen-qing Jiang; Jing Liu; Jin-ye Zhang; Bin Wang; Stephen Frye; Yi Zhang; Yan-hui Xu; Qun-ying Lei; Kun-Liang Guan; Shi-min Zhao; Yue Xiong
Journal:  Cancer Cell       Date:  2011-01-18       Impact factor: 38.585

10.  THE EFFECT OF ARGINASE ON THE RETARDATION OF TUMOUR GROWTH.

Authors:  S J BACH; D SWAINE
Journal:  Br J Cancer       Date:  1965-06       Impact factor: 7.640

View more
  579 in total

1.  Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC.

Authors:  Giovanni Blandino; Mariacristina Valerio; Mario Cioce; Federica Mori; Luca Casadei; Claudio Pulito; Andrea Sacconi; Francesca Biagioni; Giancarlo Cortese; Sergio Galanti; Cesare Manetti; Gennaro Citro; Paola Muti; Sabrina Strano
Journal:  Nat Commun       Date:  2012-05-29       Impact factor: 14.919

Review 2.  Activation of cellular metabolism during latent Kaposi's Sarcoma herpesvirus infection.

Authors:  Michael Lagunoff
Journal:  Curr Opin Virol       Date:  2016-07-18       Impact factor: 7.090

3.  Proteomic and Metabolomic Characterization of a Mammalian Cellular Transition from Quiescence to Proliferation.

Authors:  Ho-Joon Lee; Mark P Jedrychowski; Arunachalam Vinayagam; Ning Wu; Ng Shyh-Chang; Yanhui Hu; Chua Min-Wen; Jodene K Moore; John M Asara; Costas A Lyssiotis; Norbert Perrimon; Steven P Gygi; Lewis C Cantley; Marc W Kirschner
Journal:  Cell Rep       Date:  2017-07-18       Impact factor: 9.423

4.  Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520.

Authors:  Yun-Yong Park; Sang-Bae Kim; Hee Dong Han; Bo Hwa Sohn; Ji Hoon Kim; Jiyong Liang; Yiling Lu; Cristian Rodriguez-Aguayo; Gabriel Lopez-Berestein; Gordon B Mills; Anil K Sood; Ju-Seog Lee
Journal:  Hepatology       Date:  2013-05-15       Impact factor: 17.425

5.  Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma.

Authors:  Yun-Yong Park; Bo Hwa Sohn; Randy L Johnson; Myoung-Hee Kang; Sang Bae Kim; Jae-Jun Shim; Lingegowda S Mangala; Ji Hoon Kim; Jeong Eun Yoo; Cristian Rodriguez-Aguayo; Sunila Pradeep; Jun Eul Hwang; Hee-Jin Jang; Hyun-Sung Lee; Rajesha Rupaimoole; Gabriel Lopez-Berestein; Woojin Jeong; Inn Sun Park; Young Nyun Park; Anil K Sood; Gordon B Mills; Ju-Seog Lee
Journal:  Hepatology       Date:  2015-11-26       Impact factor: 17.425

6.  Profiling the Metabolism of Human Cells by Deep 13C Labeling.

Authors:  Nina Grankvist; Jeramie D Watrous; Kim A Lagerborg; Yaroslav Lyutvinskiy; Mohit Jain; Roland Nilsson
Journal:  Cell Chem Biol       Date:  2018-09-27       Impact factor: 8.116

Review 7.  Therapeutic strategies impacting cancer cell glutamine metabolism.

Authors:  Michael J Lukey; Kristin F Wilson; Richard A Cerione
Journal:  Future Med Chem       Date:  2013-09       Impact factor: 3.808

8.  Acetyl-CoA carboxylase rewires cancer metabolism to allow cancer cells to survive inhibition of the Warburg effect by cetuximab.

Authors:  Jingtao Luo; Yun Hong; Yang Lu; Songbo Qiu; Bharat K R Chaganty; Lun Zhang; Xudong Wang; Qiang Li; Zhen Fan
Journal:  Cancer Lett       Date:  2016-09-28       Impact factor: 8.679

9.  Bioenergetic properties of human sarcoma cells help define sensitivity to metabolic inhibitors.

Authors:  Sameer H Issaq; Beverly A Teicher; Anne Monks
Journal:  Cell Cycle       Date:  2014-02-10       Impact factor: 4.534

10.  Chemical Approach to Positional Isomers of Glucose-Platinum Conjugates Reveals Specific Cancer Targeting through Glucose-Transporter-Mediated Uptake in Vitro and in Vivo.

Authors:  Malay Patra; Samuel G Awuah; Stephen J Lippard
Journal:  J Am Chem Soc       Date:  2016-09-16       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.